Original Article

Psychometric properties of the Chinese version of female self-advocacy in cancer survivorship scale

Mingchun Deng a,b, Zhenqi Lu a,b,*, Anni Wang c, Xiaojun Zhang a,b, Jiajia Qiu a,b, Yi Zhang a,b, Yaqiong Chen a,b, Jun Wang a,b

a Department of Nursing, Fudan University Shanghai Cancer Center, Shanghai, China
b Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
c Fudan University School of Nursing, Shanghai, China

ARTICLE INFO

Keywords:
Psychometric properties
Female cancer survivors
Self-advocacy
Cancer survivorship

ABSTRACT

Objective: To translate Female Self-Advocacy in Cancer Survivorship (FSACS) scale and evaluate the psychometric properties of Chinese version of FSACS scale among female cancer survivors in China.

Methods: This study employed a cross-sectional design. FSACS scale was forward–backward translated and cognitive interviews were conducted for cultural adaptation. The newly translated tool was distributed to female cancer survivors to test psychometric properties, including item analysis, content validity, construct validity, criterion validity, internal consistency, and test-retest reliability.

Results: A total of 436 female cancer survivors were recruited in a Chinese tertiary cancer center from May to August in 2021. Item analysis showed statistical significance (P < 0.05) for each one and no ceiling or floor effect. The item-level content validity index ranged from 0.86 to 1.00 and the scale-level content validity index was 0.98. Three factors were extracted based on parallel analysis, and confirmatory factor analysis proved a good model fit with the original 3-factor structure. Pearson's correlation coefficient showed acceptable criterion validity. The Cronbach's α of 0.880 demonstrated the scale's internal consistency reliability, and the Alpha coefficients were 0.826, 0.763, and 0.859 for its three dimensions, respectively. The interclass correlation coefficients for test-retest reliability was 0.904 (0.870–0.891, P < 0.01) which confirmed the external reliability of the scale.

Conclusions: The Chinese version of FSACS scale proved to be a valid and reliable instrument that can be applied among Chinese female cancer survivors. Further research could be conducted in larger populations or people in different cancer stages.

Introduction

The last few years have witnessed an increase in the incidence of cancer and a decrease in death rate, particularly for a few female malignancies.1 This trend has led to a growing number of cancer survivors,2 and survivorship care has become one of the most important issues in healthcare research.

Cancer survivorship is defined as “the health and well-being of a person with cancer from the time of diagnosis until the end of life”.3 Good wellness of cancer survivors contains various dimensions,4 and healthcare providers are supposed to pay attention to each aspect.5 However, this group of people usually experienced negative emotions, persistent side-effects, and psychosocial issues.6 They still suffer from many unmet needs, which may pose challenges to their rehabilitation and quality of life in the long-term.5

The Sustainable Development Goals of 2030 agenda proposed by the United Nations involve a series of plans for the purpose of addressing global challenges and setting action goals.6 Some key elements are included in these goals, such as gender equality, good health, and well-being for individuals of all ages.7 These elements are highly relevant to the females and often interact with each other in the 2030 agenda.8 Women's health is an essential component of Sustainable Development Goals, but attention has not been paid sufficiently to female patients who suffer from life-threatening diseases like cancer.9 Furthermore, it has been argued in the Lancet that deficiencies of research pertaining to girls and women may cause problems in health...
There are obvious differences between males and females when considering symptoms, emotions, and behaviors. Evidence shows that women are more vulnerable to psychological problems such as anxiety, depression, and fatigue. At the same time, symptoms related to emotional needs and distress are more likely to be found among female patients because of their abilities to express feelings and seek support. Therefore, it is important for female cancer survivors to advocate for themselves so as to better participate in symptom management and clinical decision-making, thereby improving the quality of survivorship care. However, the lack of instruments in China to measure self-advocacy of cancer survivors limits our understanding of patients’ capacity to deal with cancer-related challenges, and hinders health professionals from providing better medical care.

Self-advocacy in the field of cancer survivorship is defined as a person’s ability to cope with diseases through internalizing available resources into thoughts and actions, and finally rise up to cancer-related challenges. The Female Self-Advocacy in Cancer Survivorship (FSACS) scale is a valid and reliable instrument that can be used to evaluate the self-advocacy ability of women with cancer. This tool is currently solely available for its original English version, so the aim of this study is to translate and validate the FSACS scale among Chinese female cancer survivors.

Methods

Design and sample

This research was a cross-sectional study carried out in a tertiary Cancer Center in China. 436 female cancer survivors were recruited from May to August in 2021. According to the GLOBOCAN estimates of a new incidence for year 2020, the top ten tumor types of women were selected to represent the main group of female patients with cancer. Based on codes from the International Statistical Classification of Diseases 10th Revision, these specific types include cancer of breast, colorectum, lung, cervix uteri, thyroid, stomach, corpus uteri, liver, ovary, and pancreas. It is suggested that 5–10 subjects are needed for each item in the process of exploratory factor analysis (EFA) and at least 200 participants for confirmatory factor analysis (CFA). Considering there are 20 items in FSACS scale, that we had to recruit additional 10 to 40 participants for the pilot study, as well as 10% withdrawal of participants was estimated, the reckoned sample size was 345–489 in total.

The inclusion criteria were: (1) ≥ 18 years old; (2) female survivors diagnosed with cancer; (3) being informed and able to complete questionnaires in Chinese. Participants who communicate impairments or mental illness were excluded. A cancer survivor was defined here as “a diagnosed individual who is still living as a survivor no matter when that diagnosis was made or whether it was successfully treated”. This study was approved by the Ethics Committee of Fudan University Shanghai Cancer Center (Approval No. 2104234-26).

Instruments

The current study utilized one self-designed questionnaire and three scales. The questionnaire comprised participants’ demographic characteristics as well as clinical information. Following is the description of the scales utilized.

The Chinese version of FSACS scale

The Chinese version of FSACS (FSACS-C) scale consists of 20 items on a six-point Likert type scale ranging from 0 (strongly disagree) to 6 (strongly agree). Three dimensions are covered, namely application of information, connected strength, and communication with healthcare providers. Cronbach’s alpha coefficients of the original scale are 0.82, 0.85, and 0.79 for each dimension.

Social support rating scale

The social support rating scale (SSRS) is a widely used scale developed by Xiao in 1989 which evaluate the extent and utilization of people’s social support. It has three dimensions, including subjective support, objective support, and utilization of social support. This tool is appropriate for Chinese context, universally accepted by people living in China. The original scale’s internal consistency ranges from 0.89 to 0.94, and its test-retest reliability is 0.92.

General self-efficacy scale

General self-efficacy scale (GSES) is a unidimensional tool for the purpose of assessing the beliefs in general people. There are 10 items in total, using four-point Likert grades ranging from points 1 (completely incorrect) to 4 (completely correct). The scale has been translated into dozens of languages, and the Chinese version of GSES has proved to be good reliability and validity. This scale has been widely used for about two decades in China.

Procedure

The study consisted of two phases. First, the FSACS scale was forward-backward translated and followed by a cross-cultural adaptation using cognitive interviewing. Second, psychometric properties were evaluated through a cross-sectional survey. Paper questionnaires were distributed in person at the hospital. Participants were recruited and a signed informed consent form was required before completing these questionnaires.

Phase 1: translation and cross-cultural adaptation

Permission of translation and adaptation had been obtained from Dr. Hagan, the developer of FSACS scale. The process of forward and backward translation was guided by Brislin’s translation model. The translation procedure was completed by 4 bilingual translators, two of whom translated the original scale from source language to Chinese, and the other two translators were English language speakers involved in the back translation process. Semantic and content equivalence could be realized through comparison and integration of these translated versions.

To make sure the items of this scale could be well-understood by the target population, cognitive interviews were performed for the purpose of cross-cultural adaptation. Face validity could also be assured during this procedure. These interviews were conducted face-to-face in quite rooms at the hospital, and the interviewing process was recorded with an audio apparatus. The privacy of participants was well-protected by researchers.

Phase 2: psychometric testing

Psychometric properties were tested based on the Classical Test Theory, including item analysis, validity, and reliability. The data analysis was performed by using IBM SPSS Statistics version 25.0 and AMOS Graphics version 23.0 for windows (IBM Corporation, the United States).

Item analysis. Item analysis was performed with the calculation of critical ratio. Items were ranked and divided into two groups according to the 25% for high and low scores, using independent t-test to examine the discrimination of each item. If the value of an item failed to reach significance, this item would be deleted because of insufficient discrimination. Additionally, the ceiling and floor effect were tested by calculating the percentage of people with highest and lowest scores. A proportion of each group less than 15% represented that the scale had no ceiling or floor effect.

Validity

Content validity. The content validity was determined by an expert panel, which was composed of clinical practitioners and researchers who...
were familiar with the methodology of psychometric testing. The expert panel assessed the correlation with the concept actually measured, using a 4-point grade with 1 being not relevant to 4 being highly relevant and succinct.\(^8\) Both the item-level content validity index (I-CVI) and the average score of scale-level content validity index (S-CVI/Ave) were evaluated. I-CVI marked 0.78 or higher and S-CVI/Ave of 0.9 or above were considered of good content validity.\(^28\)

**Criterion validity.** The concurrent validity was evaluated with Pearson correlation coefficient to examine the correlation between FSACS scale and other relevant instruments.\(^7\) Since self-advocacy is a new concept in the field of cancer survivorship, a perfect gold standard for this concept did not exist; hence, instruments related to the defining characteristics of self-advocacy were used, including GSES and the subscales of SSRS. Hypotheses were made that self-advocacy was positively correlated with self-advocacy were used, including GSES and the subscales of SSRS.

**Construct validity.** Since FSACS scale is a newly developed measurement instrument which requires cultural adaptation among Chinese population, EFA was performed to explore the latent construct of the instrument which requires cultural adaptation among Chinese population. EFA was performed to explore the latent construct of the instrument which requires cultural adaptation among Chinese population.

Kaiser-Meyer-Olkin and Bartlett's test of sphericity were performed. CFA was also applied to examine whether the construct of the instrument tested among Chinese population would be in accordance with the original scale.

Kaiser-Meyer-Olkin and Bartlett's test of sphericity were performed. CFA was also applied to examine whether the construct of the instrument tested among Chinese population would be in accordance with the original scale.

**Table 1** Participants' demographic characteristics (n = 436).

| Variables                  | n (%)       |
|----------------------------|-------------|
| Age (years)                |             |
| 18–39                      | 98 (22.48)  |
| 40–59                      | 239 (54.82) |
| ≥ 60                       | 99 (22.71)  |
| Education level            |             |
| Primary or below           | 70 (16.06)  |
| Secondary                  | 228 (52.29) |
| College                    | 62 (14.22)  |
| Bachelor                   | 76 (14.43)  |
| Master or above            | 8 (1.83)    |
| Religion                   |             |
| Non                        | 392 (89.91) |
| Buddhism                   | 33 (7.57)   |
| Christianism               | 10 (2.29)   |
| Catholicism                | 1 (0.23)    |
| Residence                  |             |
| Urban                      | 279 (63.99) |
| Rural                      | 157 (36.01) |
| Marital status             |             |
| Single                     | 21 (4.82)   |
| Married                    | 388 (88.99) |
| Divorced                   | 16 (3.67)   |
| Widowed                    | 11 (2.52)   |
| Occupational status        |             |
| Employed                   | 144 (33.03) |
| Unemployed                 | 117 (26.83) |
| Retired                    | 175 (40.14) |
| Monthly family income per person (yuan) |       |
| ≤ 3000                     | 119 (27.29) |
| 3001–6000                  | 156 (35.78) |
| 6001–9000                  | 80 (18.35)  |
| > 9000                     | 81 (18.58)  |
| Source of medical expenses |             |
| Non-medical insurance      | 50 (11.47)  |
| Medical insurance          | 386 (88.53) |

**Table 2** Participants' clinical information (n = 436).

| Variables                  | n (%)       |
|----------------------------|-------------|
| Cancer type                |             |
| Breast                     | 48 (11.01)  |
| Colorectum                 | 47 (10.78)  |
| Lung                       | 36 (8.26)   |
| Cervix uteri               | 50 (11.47)  |
| Thyroid                    | 48 (11.01)  |
| Stomach                    | 30 (6.88)   |
| Corpus uteri               | 47 (10.78)  |
| Liver                      | 35 (8.03)   |
| Ovary                      | 46 (10.55)  |
| Pancreas                   | 32 (7.34)   |
| Others                     | 17 (3.90)   |
| Metastasis                 |             |
| Non                        | 213 (48.85) |
| Local                      | 121 (27.75) |
| Distant                    | 102 (23.39) |
| Recurrence                 |             |
| Yes                        | 45 (10.32)  |
| No                         | 391 (89.68) |
| Treatment (in the past 1 year) |          |
| Surgery                    | 275 (63.07) |
| Radiotherapy               | 2 (0.46)    |
| Anticancer drug therapy\(^a\) | 70 (16.06) |
| Surgery + Radiotherapy     | 4 (0.92)    |
| Surgery + Anticancer drug therapy | 74 (16.97) |
| Radiotherapy + Anticancer drug therapy | 2 (0.46) | More than three | 9 (19.57) |
| Course of disease          |             |
| 0–6 months                 | 351 (80.50) |
| –2 years                   | 50 (11.47)  |
| –5 years                   | 23 (5.28)   |
| > 5 years                  | 12 (2.75)   |

\(^a\) Anticancer drug therapy includes chemotherapy, targeted therapy and immunotherapy.

**Table 3** Correlation of FSACS with GSES and subscales of SSRS (n = 436).

| Variables | SSRS | GSES |
|-----------|------|------|
|           | $S_1$ | $S_2$ | $S_3$ |
| FSACS     | 0.155** | 0.143** | 0.162** | 0.339** |
| F1        | 0.101*  | 0.125** | 0.116* | 0.391** |
| F2        | 0.096*  | 0.105*  | 0.043  | 0.147** |
| F3        | 0.160** | 0.103*  | 0.193** | 0.212** |

**Table 4** Outcomes of parallel analysis (n = 218).

| Eigenvalues | Raw data | Means | Percentyl |
|-------------|----------|-------|-----------|
| Root        |          |       |           |
| 1           | 6.692,97 | 1.577,96 | 1.683,23 |
| 2           | 2.644,84 | 1.471,10 | 1.545,98 |
| 3           | 1.556,64 | 1.388,76 | 1.458,89 |
| 4           | 1.084,12 | 1.319,73 | 1.376,75 |
| 5           | 0.822,85 | 1.256,66 | 1.308,04 |

explained by the factor drawn from simulated random data, this factor would be valueless to be retained.\(^20\)

As for CFA, chi-square test was performed, and CFA was evaluated by a series of indexes, such as ratio of chi-square and degree of freedom ($\chi^2/df$), goodness-of-fit Index, adjusted goodness-of-fit, comparative fit index, incremental fit index, normed fit index and root mean square error of approximation. Modification could be appropriately used if necessary.

**Reliability.** Cronbach’s alpha coefficient was calculated in order to evaluate the internal consistency of the scale and its subscales. Before this
procedures, unidimensional feature was tested through factor analysis to meet the prerequisite of evaluating internal consistency for each dimension.

Since self-advocacy was considered a variable that does not change significantly over a short period of time, the stability was examined by calculating intraclass correlation coefficient \( r_{ic} \) among 15–30 participants over a 2-week interval, so as to evaluate the test-retest reliability. In the process of filling in the questionnaires, participants were provided with almost the same conditions between their two tests, including testing spots, guidance of the researcher, their health status, and the treatments they received.

### Results

We distributed 483 questionnaires and a total of 436 cancer survivors effectively completed these questionnaires, so the response rate was 90.27%. Participants’ demographic characteristics are showed in Table 1 and their clinical information is demonstrated in Table 2.

Participants were from 18 to 79 years of age, with a mean of 49.7 (standard deviation \( SD \) = 12.4) years old. About half of the participants received secondary education, one third attended college and 70 (16.06%) individuals got primary education or below. Most of the participants (89.91%) did not practice religion, 279 (63.99%) individuals live in cities, and 388 (88.99%) were in their marriage. Most women had at least one or two children, while a small number of them (7.24%) did not have any child. For working status, 144 (33.03%) participants were currently employed, and the others were unemployed or retired.

Our sample contained the main categories of female malignancies and the details are shown in Table 2. Nearly half of the patients did not have metastatic tumors, while 121 (27.75%) patients developed local metastasis and 102 (23.39%) patients suffered from distant metastasis. Most survivors (48.85%) did not experience the recurrence of cancer. 275 (63.07%) participants received treatment of surgery within 1 year, and 351 (80.50%) patients experienced course of disease less than 6 months.

### Phase 1: translation and cross-cultural adaptation

We completed the translation process with the participation of four bilingual translators, and then a panel of experts held a meeting to discuss and integrate these translated versions. In the end, we formed an initial Chinese version of FSACS (FSACS-C) scale. For cultural adaptation, we conducted a three-round cognitive interviewing where 25 interviewees

---

**Table 5**

Factor loadings with exploratory factor analysis (\( n = 218 \)).

| Component | Factor 1 | Factor 2 | Factor 3 |
|-----------|----------|----------|----------|
| Item 2    | 0.769    |          |          |
| Item 5    | 0.745    |          |          |
| Item 3    | 0.731    |          |          |
| Item 6    | 0.693    |          |          |
| Item 11   | 0.672    |          |          |
| Item 1    | 0.630    |          |          |
| Item 4    | 0.594    |          |          |
| Item 7    |          | 0.811    |          |
| Item 10   |          | -0.804   |          |
| Item 8    |          | 0.756    |          |
| Item 9    |          | -0.725   |          |
| Item 12   |          | 0.566    |          |
| Item 13   |          | 0.779    |          |
| Item 15   |          | 0.764    |          |
| Item 16   |          | 0.757    |          |
| Item 20   |          | 0.724    |          |
| Item 17   |          | 0.718    |          |
| Item 14   |          | 0.693    |          |
| Item 18   |          | 0.684    |          |
| Item 19   |          | 0.616    |          |

Extraction Method: Principal component analysis. Rotation Method: Promax with Kaiser normalization.

---

**Table 6**

Model fit indexes of the three-factor structure (\( n = 218 \)).

| Modification | \( \chi^2 \) | \( \chi^2/df \) | GFI | AGFI | IFI | NFI | TLI | CFI | RMSEA |
|--------------|-------------|----------------|-----|------|-----|-----|-----|-----|-------|
| Before       | 334.557     | 2.003          | 0.869 | 0.836 | 0.898 | 0.815 | 0.882 | 0.897 | 0.068 |
| After        | 244.571     | 1.510          | 0.901 | 0.872 | 0.950 | 0.865 | 0.940 | 0.949 | 0.048 |

AGFI, adjusted GFI; CFI, comparative fit index; GFI, goodness-of-fit index; IFI, incremental fit index; NFI, normed fit index; RMSEA, root mean square error of approximation.
were involved. The interviewees were from 18 to 70 years of age, in different residential places, of various educational levels as well as employment status. We adapted the scale at the end of each interviewing round, and finally gained a well-understood instrument that could be accepted by people of diverse backgrounds.

Phase 2: psychometric testing

We examined psychometric properties of FSACS-C scale, and randomly divided the collected data into two portions for EFA and CFA, respectively. The split of data was performed in SPSS software and a sample size of 50% was set by using the ‘select cases’ menu. Item analysis showed statistical significance for each ($P < 0.05$), suggesting fine discrimination so we did not delete any item. The proportion of those who gained the highest and lowest scores were both less than 15%, indicating no ceiling or floor effect in this scale.

Validity

We invited seven healthcare professionals to participate in the process of content validation. The results showed I-CVI ranged from 0.86 to
0.10 and S-CVI/Ave was 0.98, which indicated good content validity. We examined concurrent validity of FSACS-C scale by testing the Pearson’s correlation. Statistics showed the coefficient of 0.339 (P < 0.01) between FSACS-C and GSES, and that of 0.193 (P < 0.01) between FSACS-C and the subscale (social support utilization dimension) of SSRS, which is presented in Table 3.

Based on PA, we used principal components and generated random normal data at the same time. It was suggested by the mean and percentile of PA that the most appropriate number of factors was three (Table 4), so we finally choose to retain 5 factors. And then we set 3 as the fixed number of factors, by using “dimension reduction” of SPSS. The factor loadings with EA are demonstrated in Table 5. The curve of scree plot with parallel analysis is showed in Fig. 1.

We examined the three-factor model in terms of the construct of the original scale by using CFA. The three-factor structure was evaluated by model fit indexes which were presented in Table 6, and the three-factor model was showed in Fig. 2.

Reliability

A Cronbach’s α of 0.880 confirmed the internal consistency of the 20-item scale, and 0.826, 0.763, and 0.859 for each subscale. It was demonstrated in Table 7 that the Alpha coefficient did not increase with each item deleted, so we retained all the items in FSACS-C.

As for test-retest reliability, we examined 21 participants over 14 days interval, providing them with the same environment of testing between these two measurements. The interclass correlation coefficients was 0.904 (0.870–0.891, P < 0.01), indicating high external reliability of the scale.

Discussion

In this study, we translated and validated the FSACS scale and confirmed its reliability. We regard this scale as a useable tool to measure self-advocacy. Although the concept of self-advocacy is somewhat impenetrable before explaining, the evaluation of this concept can be quantified with psychometric scales to assess latent variables. Our study has demonstrated the acceptability and feasibility of applying this tool in the target population.

During the process of cultural adaptation, cognitive interviewing is considered a practical approach which helps to confirm the face validity of a cross-cultural psychometric instrument. The structure of FSACS-C performed by EFA using parallel analysis to determine the number of common factors by using this newly translated tool. PA is considered an effective method compared with certain traditional approaches. For example, the criterion of eigenvalue ≥ 1, may lead to over-extraction of the number of common factors and affect the outcome of construct validity.21 As we initially examined, it was slightly different from the original scale when employing eigenvalues for dimensionality assessment, but PA can solve this problem. Furthermore, CFA showed the model fit was acceptable based on the concept framework of self-advocacy, so we finally adopted the three-factor structure model for FSACS-C.

Among Chinese population, FSACS-C has assessed three dimensions with regard to expressing their needs, communicating with healthcare providers and gaining support from their social networks. It provides us with an opportunity to better understand how women diagnosed with cancer involve in clinical decisions and use available resources.

The translation and adaptation of this tool may lead to additional potential benefits for female cancer survivors. Specifically, this measurement tool can help medical staff assess cancer sufferers’ abilities to advocate for themselves and active participation in clinical decision-making when facing challenges during their cancer journey. It can also assist healthcare providers in identifying populations with low self-advocacy and discovering relevant facilitators and barriers. Furthermore, a reliable and valid psychometric tool plays an important role in evaluating intervention studies. If intervention programmes for cancer survivors pertaining to self-advocacy is implemented in the future, this scale, which has been applicable in Chinese context, can serve as a good psychometric tool.

Limitations of this study may be as follows. First, this cross-sectional study was conducted solely in one cancer center. The results may not apply to female cancer population of all regions in China, so this tool may not be valid for all female Chinese cancer survivors. There might also be selective bias in terms of resources available and information gained, as cancer survivors living in remote regions and undeveloped areas are less likely to enroll in large cancer centers particularly in first-tier cities. Second, most of the participants were in their active treatment when being surveyed, with a short-term experience of cancer since their initial diagnosis. We aligned with our participants with that of the original scale, which aimed at cancer survivors of all stages in terms of the definition by the National Cancer Institute.14 As a result, the recruitment of participants was not evenly distributed to different stages but largely involved those who received their initial therapy.

It is suggested that future study can be conducted in other regions of the country and incorporate participants with various course of disease, particularly survivors who receive extended period of a cancer treatment and suffer from long-term conditions.

Conclusions

FSACS-C scale is a valid and reliable instrument to evaluate how Chinese female cancer survivors advocate for themselves. Further research can be conducted among women with cancer in different stages of cancer.

Authors’ contributions

Conceived and designed the analysis: Mingchun Deng, Zhenqi Lu, Anni Wang. Collected the data: Mingchun Deng, Zhenqi Lu, Yi Zhang, Yaqiong Chen, Jun Wang. Contributed data or analysis tools: Jiajia Qiu, Xiaojia Zhang, Anni Wang. Performed the analysis: Mingchun Deng, Anni Wang. Wrote the paper: Mingchun Deng, Zhenqi Lu, Anni Wang, Xiaojia Zhang, Jiajia Qiu, Yi Zhang, Yaqiong Chen, Jun Wang.

Ethics statement

This study was approved by the Ethics Committee of Fudan University Shanghai Cancer Center (Approval No. 2104234-26).
Funding
This study was funded by Fudan University School of Nursing.

Declaration of competing interest
None declared.

Acknowledgments
The authors want to thank the staff of the cancer hospital for assisting in data collection, and also would like to thank the female patients involved in this research.

References
1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021 Jan;71(1):7–33. https://doi.org/10.3322/caac.21654.
2. Jefford M. Improving the care of adult cancer survivors. Asia-Paciﬁc J Oncol Nursing. Jan-Mar 2020;7(1):2–5. https://doi.org/10.4103/apjon.apjon.42.19.
3. National Cancer Institute. Survivorship. Website. https://www.cancer.gov/publications/dictionaries/cancer-terms/del/survivorship?redirect=dictionaries/cancer-terms/del/survivorship#s0140-6736(19)30283-1. Accessed April 21, 2022.
4. National Cancer Institute. Survivorship. Website. https://www.cancer.gov/publications/dictionaries/cancer-terms/del/survivorship?redirect=dictionaries/cancer-terms/del/survivorship#s0140-6736(19)30283-1. Accessed April 21, 2022.
5. Malosiotis A, Yates P, Li Q, et al. Mapping patient supportive care needs, quality-of-life perceptions and current symptoms in cancer survivors across the Asia-Paciﬁc region: results from the International STEP Study. Ann Oncol. 2017;28(10):2552–2558. https://doi.org/10.1093/annonc/mdx350.
6. United Nations. Sustainable development goals (SDG). Website http://sdg.org/. Accessed April 21, 2022.
7. Magar V. Gender, health and the sustainable development goals. Bull World Health Organ. Nov 1 2015;93(11):743. https://doi.org/10.2471/BLT.15.165027.
8. Manandhar M, Hawkes S, Buse K, Nosrati E, Magar V. Gender, health and the 2030 agenda for sustainable development. Lancet. 2015;386(9999):1165–1166. https://doi.org/10.1016/S0140-6736(15)60497-4.
9. Hawkes S, Haeem F, Assnallah-Shakhrani H. Measurement and meaning: reporting sex in health research. Lancet. 2019;393(10171):497–499. https://doi.org/10.1016/S0140-6736(19)30283-1.
10. Minkowski C. Gender differences in pain, fatigue, and depression in patients with cancer. J Nutr Cancer Inst Monogr. 2004;2004(32):139–143. https://doi.org/10.1093/jncimonomographs/gh024.
11. Keogh E. Gender differences in the nonverbal communication of pain: a new direction for sex, gender, and research? Pain. Oct 2014;155(10):1927–1931. https://doi.org/10.1016/j.pain.2014.06.024.
12. Samulowitz A, Gremyr I, Eriksson E, Hessing G. ’Brave men’ and ’emotional women’: a theory-guided literature review on gender bias in health care and gendered norms towards patients with chronic pain. Pain Res Manag. 2018;2018:6358624. https://doi.org/10.1155/2018/6358624.
13. Xiao S. The theoretical basis and research application of social support rating scale. J Clin Psychol. 1994(2):98–100.
14. Hagane TL, Donovan HS. Self-advocacy and cancer: a concept analysis. J Adv Nurs. Oct 2013;69(10):2348–2359. https://doi.org/10.1111/jan.12084.
15. Sung H, Ferlay J, Siegel RL, et al. Global cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA A Cancer J Clin. May 2021;71(3):209–249. https://doi.org/10.3322/ caac.21660.
16. DeVellis RF. Scale Development: Theory and Applications. Thousand Oaks, California: Sage Publications; 2012.
17. Hagan TL, Cohen SM, Rosenzweig MQ, Zom K, Stone CA, Donovan HS. The female self-advocacy in cancer survivorship scale: a validation study. J Adv Nurs. Apr 2018;74(4):976–987. https://doi.org/10.1111/jan.13498.
18. Soma VP, Rojjanasrirat W. Translation, adaptation and validation of instruments or scales for use in cross-cultural health care research: a clear and user-friendly guideline. J Eval Clin Pract. Apr 2011;17(2):268–274. https://doi.org/10.1111/j.1365-2753.2010.01434.x.
19. Twombly R. What’s in a name: is a cancer survivor? J Natl Cancer Inst. Oct 2 2004;96(19):1414–1415. https://doi.org/10.1093/jnci/96.19.1414.
20. Xiao S. The theoretical basis and research application of social support rating scale. J Clin Psychol. 1994(2):98–100.
21. Cheung SK, Sun SY. Assessment of optimistic self-beliefs: further validation of the Chinese version of the General Self-Efficacy Scale. Psychol Rep. Dec 1999;85(3 Pt 2):1221–1224. https://doi.org/10.2466/pr0.1999.85.3f.1221.
22. Wang C, Hu Z, Liu Y. Reliability and validity of general self-efficacy scale. Chinese J Appl Psychol. 2001(1):37–40.
23. Briddin RW. Back-translation for cross-cultural research. J Cross Cult Psychol. 1970;1(3):185–216. https://doi.org/10.1016/13591045(70)900301.
24. Maneesriwongul W, Dixon JK. Instrument translation process: a methods review. J Adv Nurs. Oct 2004;48(2):175–186. https://doi.org/10.1111/j.1365-2648.2004.03185.x.
25. Willis GB, Miller K, Willis GB, Miller K. Cross-cultural cognitive interviewing: seeking comparability and enhancing understanding. Field Methods. 2011;23(4):331–341. https://doi.org/10.1177/1525822x11416092.
26. Miller K. Cognitive Interviewing Methodology: Spain: Wiley; 2014.
27. de Vet HCW, Terwee CB, Mokkink LB, Knol DL. Measurement in Medicine: A Practical Guide. Cambridge: Cambridge University Press; 2011.
28. Politi DF, Beck CT, Owen SV. Is the CVI an acceptable indicator of content validity? Appraisal and recommendations. Res Nurs Health. 2007 Aug;30(4):459–467. https://doi.org/10.1002/nur.20195.
29. Gaskin CJ, Happell B. On exploratory factor analysis: a review of recent evidence, an assessment of current practice, and recommendations for future use. Int J Nurs Stud. Mar 2014;51(3):511–521. https://doi.org/10.1016/j.ijnurstu.2013.10.005.
30. Horn JL. A rationale and test for the number of factors in factor analysis. Psychometrika. 1965;30(2):179–185. https://doi.org/10.1007/BF02289447.
31. Lim S, Jahng S. Determining the number of factors using parallel analysis and its recent variants. Psychol Methods. Aug 2019;24(4):452–467. https://doi.org/10.1037/met0000230.
32. Silverstein AB. Update on the parallel analysis criterion for determining the number of principal components. Psychol Rep. Oct 1990;67(2):511–514. https://doi.org/10.2466/pr0.1990.67.2.511.
33. Silverstein AB. Note on the parallel analysis criterion for determining the number of common factors or principal components. Psychol Rep. Oct 1987;61(2):351–354. https://doi.org/10.2466/pr0.1987.61.2.351.
34. Koo TK, Li MY. A guideline of selecting and reporting intraclass correlation coefﬁcients for reliability research. J Clin Epidemiol. Jun 2016;75(2):155–163. https://doi.org/10.1016/j.jclinepi.2016.02.012.
35. Mukaka MM. Statistics corner: a guide to appropriate use of correlation coefficient in medical research. Malawi Med J. Sep 2012;24(3):69–71.